SUBSCRIBE
SUBSCRIBE

Kardigan

NEWS
Stick figure balances on a wooden block, navigating a wave with a shark fin visible below, representing business risk, danger and survival
IPO
Sky-high Parabilis, Kailera IPOs spur optimism—but only for derisked biotechs
Biotechs are benefitting from the AI tech frenzy and inflation, but validated pipelines and careful planning are still key to the recent record-setting IPOs, experts say.
June 11, 2026
 · 
5 min read
 · 
Annalee Armstrong
Yellow diagram of pulses on a stack of red paper hearts. Illustration of the concept of healthy lifestyles and cardiovascular related diseases
Cardiovascular disease
Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 Readout
While tonlamarsen missed one of two co-primary endpoints, Kardigan says the drug has shown a clinically meaningful effect on blood pressure, supporting advancement into Phase 2b.
March 30, 2026
 · 
2 min read
 · 
Annalee Armstrong
NextGen
BioSpace’s NextGen Class of 2026 Attracts Big Bucks From Tight Wallets
From biotech veterans to embattled modalities to a new wave of RNAi therapeutics, BioSpace’s NextGen Class of 2026 emerged during a tough fundraising environment in 2025. Check out the 15 battle-tested companies that caught our eye.
January 7, 2026
 · 
2 min read
 · 
Annalee Armstrong
Vector design of a human heart with flat color and multiple colors line heart shapes. Square composition.
Series A
MyoKardia Alumni Launch Kardigan with $300M to Tackle Heart Disease
After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are back together with a mission to make cardiovascular disease curable and preventable.
January 10, 2025
 · 
2 min read
 · 
Heather McKenzie
  • NextGen Class of 2026 Badge
JOBS
IN THE PRESS
Press Releases
Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 23, 2026
 · 
2 min read
Press Releases
Kardigan Announces Pricing of Upsized Initial Public Offering
June 18, 2026
 · 
4 min read
Press Releases
Kardigan Announces Positive Phase 2 Data for Tonlamarsen in Patients with Uncontrolled Hypertension Presented as Late-Breaker at ACC.26 and Simultaneously Published in JACC
March 30, 2026
 · 
7 min read
Press Releases
Kardigan Announces Multiple Presentations at ACC.26 from its Late-Stage Portfolio of Personalized Cardiovascular Medicines
March 17, 2026
 · 
6 min read
Press Releases
Kardigan Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference and Provides Corporate Update for 2026
January 7, 2026
 · 
5 min read
Press Releases
Kardigan Presents Positive Phase 2 Data on Ataciguat in Patients With Moderate Calcific Aortic Valve Stenosis at American Heart Association Scientific Sessions 2025
November 10, 2025
 · 
5 min read
Press Releases
Kardigan Acquires Prolaio to Create a Pioneering Heart Health Company with One-of-a-Kind Integrated Cardiovascular Data and Therapeutics Platform
November 6, 2025
 · 
5 min read
Press Releases
Kardigan Raises $254 Million Series B to Advance Late-Stage Portfolio of Personalized Cardiovascular Medicines
October 15, 2025
 · 
2 min read
Press Releases
Kardigan Announces Presentation of Positive Phase 2a Data for Danicamtiv in Patients with Dilated Cardiomyopathy at HFSA Annual Scientific Meeting 2025
September 30, 2025
 · 
5 min read
Press Releases
Kardigan Advances Late-Stage Portfolio of Personalized Cardiovascular Medicines in Dilated Cardiomyopathy, Acute Severe Hypertension and Calcific Aortic Valve Stenosis
September 25, 2025
 · 
6 min read
Load More